Extended Data Fig. 6: Sex-specific analysis of primary and key secondary endpoints in the RFITT population at week 2.
a, Binary symptoms. Forest plot graphs represent odds ratios and the respective lower/upper 95% confidence intervals (CI). Resolution of performance drop: nicotinamide: n = 191 (73 males, 118 females); placebo: n = 188 (77 males, 111 females). Resolution of fatigue: nicotinamide: n = 199 (82 males, 117 females); placebo: n = 198 (78 males, 120 females). The number of participants indicates those included in the analysis due to the presence of performance drop or fatigue at baseline, respectively. b, Complaint scale. Forest plot graphs represent Hedges’ g and lower/upper CI. Improvement in the ability to perform normal activities: nicotinamide: n = 103 (41 males, 62 females); placebo: n = 95 (34 males, 61 females). Improvement of cough: nicotinamide: n = 44 (17 males, 27 females); placebo: n = 33 (8 males, 25 females). The number of participants indicates those included in the analysis due to the presence of a sufficiently severe reduction in the ability to perform normal activities or a sufficiently severe cough (a value of >3 on the 6-point complaint scale) at baseline, respectively.
